U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H23ClFNO2
Molecular Weight 375.8649
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HALOPERIDOL

SMILES

C(CC(=O)c1ccc(cc1)F)CN2CCC(CC2)(c3ccc(cc3)Cl)O

InChI

InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/015923s079lbl.pdf

Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others.

Originator

Curator's Comment:: Haloperidol was synthesized on the 11th of February 1958 at the Janssen Laboratories, in Belgium.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
17.0 nM [EC50]
53.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HALDOL

Approved Use

HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder.

Launch Date

5.059584E11
Primary
HALDOL

Approved Use

HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. HALDOL is indicated for the control of tics and vocal utterances of Tourette’s Disorder.

Launch Date

5.059584E11
Doses

Doses

DosePopulationAdverse events​
0.9 mg single, oral
Overdose
Dose: 0.9 mg
Route: oral
Route: single
Dose: 0.9 mg
Sources:
unknown, 11 years
n = 1
Health Status: unknown
Age Group: 11 years
Sex: M
Population Size: 1
Sources:
Other AEs: Drowsiness...
Other AEs:
Drowsiness (1 patient)
Sources:
2 mg 4 times / day multiple, intramuscular
Recommended
Dose: 2 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 2 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: dementia-related psychosis
Age Group: adult
Sources:
5 mg 3 times / day multiple, oral
Recommended
Dose: 5 mg, 3 times / day
Route: oral
Route: multiple
Dose: 5 mg, 3 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: dementia-related psychosis
Age Group: adult
Sources:
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Other AEs: Torsades de pointes, Electrocardiogram QTc interval prolonged...
Other AEs:
Torsades de pointes (serious, 2 patients)
Electrocardiogram QTc interval prolonged (below serious, 13 patients)
Sources:
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Other AEs: Cheilitis, Constipation...
Other AEs:
Cheilitis (below serious, 1 patient)
Constipation (below serious, 2 patients)
Salivary hypersecretion (below serious, 1 patient)
Vomiting (below serious, 1 patient)
Malaise (below serious, 2 patients)
Thirst (below serious, 1 patient)
Fall (below serious, 1 patient)
Blood pressure decreased (below serious, 1 patient)
Weight increased (below serious, 1 patient)
Increased appetite (below serious, 1 patient)
Arthralgia (below serious, 1 patient)
Osteoarthritis (below serious, 1 patient)
Akathisia (below serious, 3 patients)
Dystonia (below serious, 3 patients)
Headache (below serious, 1 patient)
Sedation (below serious, 1 patient)
Tremor (below serious, 2 patients)
Depressive symptom (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Mania (below serious, 1 patient)
Pruritus (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
0.9 mg single, oral
Overdose
Dose: 0.9 mg
Route: oral
Route: single
Dose: 0.9 mg
Sources:
unknown, 11 years
n = 1
Health Status: unknown
Age Group: 11 years
Sex: M
Population Size: 1
Sources:
Electrocardiogram QTc interval prolonged below serious, 13 patients
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Torsades de pointes serious, 2 patients
10 mg 2 times / day steady, intravenous
Dose: 10 mg, 2 times / day
Route: intravenous
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 192
Health Status: unhealthy
Condition: Delirium
Population Size: 192
Sources:
Arthralgia below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Blood pressure decreased below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Cheilitis below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Depressive symptom below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Fall below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Headache below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Increased appetite below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Insomnia below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Mania below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Osteoarthritis below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Pruritus below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Salivary hypersecretion below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Sedation below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Thirst below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Vomiting below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Weight increased below serious, 1 patient
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Constipation below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Malaise below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Tremor below serious, 2 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Akathisia below serious, 3 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
Dystonia below serious, 3 patients
10 mg 2 times / day steady, oral
Dose: 10 mg, 2 times / day
Route: oral
Route: steady
Dose: 10 mg, 2 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: Bipolar I Disorder
Population Size: 20
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
moderate [Ki 7.2 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >30 uM]
no [IC50 >50 uM]
no
yes [Activation 31.6228 uM]
yes [IC50 10.7 uM]
yes [IC50 141.9 uM]
yes [IC50 2.87 uM]
yes [IC50 25.3 uM]
yes [IC50 25.4 uM]
yes [IC50 3.6 uM]
yes [IC50 4.69 uM]
yes [IC50 8.2 uM]
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely [Km 33 uM]
major
major
major
major
minor
minor
minor
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Atypical tardive dyskinesia.
1975 May
Drug-induced dystonia.
1975 May
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.
1976 Aug
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
1999
Locomotor activity and accumbens Fos expression driven by ventral hippocampal stimulation require D1 and D2 receptors.
1999
Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats.
1999
Neurotransmitter-mediated open-field behavioral action of CGRP.
1999
Synergistic interactions between ampakines and antipsychotic drugs.
1999 Apr
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury.
1999 Dec
Haloperidol-induced within-session response decrement patterns and catalepsy in rats: behavioural dissociation.
1999 Feb
Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist.
1999 Feb
Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
1999 Jul
Safety of amisulpride (Solian): a review of 11 clinical studies.
1999 Jul
New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
1999 Jun
Molecular and behavioral effects mediated by Gs-coupled adenosine A2a, but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration.
1999 Mar
Behavioral effects following single and combined maternal exposure to PCB 77 (3,4,3',4'-tetrachlorobiphenyl) and PCB 47 (2,4,2',4'-tetrachlorobiphenyl) in rats.
1999 Mar-Apr
Effects of SCH 23390, raclopride, and haloperidol on morphine withdrawal-induced aggression in male mice.
1999 Sep
Identification of quantitative trait loci for haloperidol-induced catalepsy on mouse chromosome 14.
1999 Sep
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
2000 Apr
Estrogen priming modulates autoreceptor-mediated potentiation of dopamine uptake.
2000 Aug 11
Effect of genetic cross on the detection of quantitative trait loci and a novel approach to mapping QTLs.
2000 Dec
Prolonged upper airway instability in the parenteral use of benzodiazepine with levomepromazine.
2000 Feb
Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.
2000 Jan 3
Manic episode in an ifosfamide-treated patient.
2000 Jan-Feb
Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy.
2000 Jun
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.
2000 Mar
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.
2000 May
Biperiden hydrochlorate ameliorates dystonia of rats produced by microinjection of sigma ligands into the red nucleus.
2000 Nov
Enhancement of haloperidol-induced catalepsy by nicotine: an investigation of possible mechanisms.
2000 Nov
Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain.
2000 Oct
Haloperidol-induced impotence improved by switching to olanzapine.
2000 Sep-Oct
FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration.
2001 Feb
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
2001 Feb 13
Double activity imaging reveals distinct cellular targets of haloperidol, clozapine and dopamine D(3) receptor selective RGH-1756.
2001 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be taken orally https://www.drugs.com/ppa/haloperidol.html
Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. Depending on the response of the patient, subsequent doses may be given, administered as often as every hour, although 4 to 8 hour intervals may be satisfactory.
Route of Administration: Intramuscular
10 uM Haloperidol induced a 54% decrease in the mRNA expression of ABCA1 in murineperitoneal macrophages.
Name Type Language
HALOPERIDOL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
HALOPERIDOL DECANOATE SPECIFIED IMPURITY G [EP]
Common Name English
HALOPERIDOL COMPONENT OF VESALIUM
Brand Name English
EUKYSTOL
Common Name English
VESALIUM COMPONENT HALOPERIDOL
Brand Name English
HALOPERIDOL [HSDB]
Common Name English
HALOPERIDOL [WHO-IP]
Common Name English
SIGAPERIDOL
Common Name English
HALDOL
Brand Name English
KESELAN
Common Name English
ALOPERIDIN
Common Name English
HALOPERIDOL [WHO-DD]
Common Name English
NSC-170973
Code English
HALOPERIDOL [EP MONOGRAPH]
Common Name English
R-1625
Code English
NSC-615296
Code English
HALOPERIDOLUM [WHO-IP LATIN]
Common Name English
SERENELFI
Common Name English
SERENASE
Common Name English
BIOPERIDOLO
Common Name English
1-BUTANONE, 4-(4-(4-CHLOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-(4-FLUOROPHENYL)-
Systematic Name English
HALOPERIDOL [USP]
Common Name English
HALOPERIDOL [MI]
Common Name English
SERENACE
Common Name English
HALOPERIDOL [USP MONOGRAPH]
Common Name English
HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP]
Common Name English
HALOPERIDOL [MART.]
Common Name English
NEURODOL
Common Name English
LINTON
Common Name English
HALOPERIDOL [ORANGE BOOK]
Common Name English
HALOPERIDOL [USAN]
Common Name English
HALOPERIDOL [INN]
Common Name English
HALOPERIDOL [VANDF]
Common Name English
DOZIC
Common Name English
HALOPERIDOL [USP-RS]
Common Name English
Classification Tree Code System Code
LIVERTOX 476
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NDF-RT N0000180182
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-ATC N05AD01
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 24.1
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
WHO-VATC QN05AD01
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NCI_THESAURUS C323
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
NCI_THESAURUS C66883
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HALOPERIDOL
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY Description: A white to faintly yellowish, amorphous or microcrystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 50 parts of ethanol (~750 g/l) TS and in 200 parts of ether R. Category: Neuroleptic. Storage: Haloperidol should be kept in a well-closed container, protected from light. Definition: Haloperidol contains not less than 98.0% and not more than 101.0% of C21H23ClFNO2, calculated with reference to the dried substance.
IUPHAR
86
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
DRUG BANK
DB00502
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
HSDB
3093
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
LACTMED
Haloperidol
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
WIKIPEDIA
HALOPERIDOL
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
FDA UNII
J6292F8L3D
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
RXCUI
5093
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY RxNorm
CAS
52-86-8
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
PUBCHEM
3559
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL54
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
MESH
D006220
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
USP_CATALOG
1303002
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY USP-RS
ECHA (EC/EINECS)
200-155-6
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
MERCK INDEX
M5904
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C537
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
EPA CompTox
52-86-8
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
EVMPD
SUB08005MIG
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
INN
918
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY
DRUG CENTRAL
1353
Created by admin on Fri Jun 25 20:55:26 UTC 2021 , Edited by admin on Fri Jun 25 20:55:26 UTC 2021
PRIMARY